Alembic (APLLTD) | Stock Overview & Key Data
Alembic Performance Comparison
Stock Range
Today's Range
Low: ₹935.00
High: ₹950.30
on August 8, 2025
52 Week Range
Low: ₹725.20
High: ₹1,303.90
on March 3, 2025
on October 9, 2024
All-Time High: ₹1,303.90 on October 7, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR184.0B
EPS
30.70
P/E Ratio (TTM)
30.50
Forward P/E
21.52
P/B Ratio
3.55
PEG Ratio
21.52
Div. Yield
1.09%
ROE
11.24%
Beta
0.467
Debt to Equity
24.23
Financial Highlights
Profitability
Gross Margin
76.18%
Operating Margin
12.13%
Profit Margin
8.84%
Returns and Earnings
Return on Assets (TTM)
7.51%
Return on Equity (TTM)
11.24%
EBITDA
INR11.0B
Net Income (TTM)
INR6.0B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR347.02
Quarterly Revenue Growth (YoY)
9.50%
Quarterly Earnings Growth (YoY)
14.60%
Dividend Information
Last 12-Month Dividend
₹11.00
Current Dividend Yield
1.09%
3-Year Average Dividend Yield
1.17%
3-Year Average Annual Dividend
₹13.33
3-Year Total Dividends
₹40.00
Ex-Dividend Date
July 29, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Alembic APLLTD | 184.02B Mid-cap | -2.38% | -6.43% | 3.77% | 5.42% | -10.75% | -15.92% | 45.65% | -8.45% |
| Sun Pharmaceutical SUNPHARMA | 3.84T Large-cap | -2.63% | -5.12% | -10.20% | -8.38% | -16.03% | -8.55% | 73.73% | 198.65% |
| Divi's Laboratories DIVISLAB | 1.63T Large-cap | -7.03% | -14.75% | -0.77% | -0.41% | -2.61% | 22.45% | 58.73% | 91.42% |
| Jubilant Pharmova JUBLPHARMA | 174.95B Mid-cap | -5.02% | -5.59% | 24.87% | 10.08% | 1.88% | 27.78% | 214.12% | 81.50% |
| Natco Pharma NATCOPHARM | 165.27B Mid-cap | -2.50% | -7.83% | 13.12% | -29.19% | -35.03% | -36.97% | 40.23% | 9.43% |
| Neuland Laboratories NEULANDLAB | 164.62B Mid-cap | 0.63% | 11.90% | 6.29% | -10.73% | -8.36% | 13.74% | 1,100.26% | 1,532.07% |
Ownership & Short Interest
Insider Ownership
70.45%
Institutional Ownership
16.51%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
121K
Average 90-Day Volume
674K
Alembic Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Alembic would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is APLLTD's 52-week high and low?
- In the last 52 weeks, Alembic reached a high of ₹1,303.90 (on October 9, 2024) and a low of ₹725.20 (on March 3, 2025).
- What is the market cap and P/E ratio for APLLTD?
- Curious about Alembic's size and valuation? Its market capitalization stands at 184.02B. When it comes to valuation, the P/E ratio (trailing twelve months) is 30.50, and the forward P/E (looking ahead) is 21.52.
- Does APLLTD pay dividends? If so, what's the yield?
- Yes, Alembic is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 1.09%, and the company has paid an average of ₹13.33 per share annually over the past 3 years.
- Who are Alembic's main competitors or similar companies to consider before investing?
When looking at Alembic, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.84T Healthcare Drug Manufacturers - Specialty & Generic -8.55% 73.73% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 22.45% 58.73% Jubilant Pharmova
JUBLPHARMA174.95B Healthcare Drug Manufacturers - Specialty & Generic 27.78% 214.12% Natco Pharma
NATCOPHARM165.27B Healthcare Drug Manufacturers - Specialty & Generic -36.97% 40.23% Neuland Laboratories
NEULANDLAB164.62B Healthcare Drug Manufacturers - Specialty & Generic 13.74% 1,100.26% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Alembic Pharmaceuticals Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Alembic's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 11.24%, the Debt to Equity ratio from the most recent quarter is 24.23, and its Gross Profit Margin stands at 76.18%.
- What is the recent revenue and earnings growth for APLLTD?
- Looking at Alembic's growth, its revenue over the trailing twelve months (TTM) was INR68B. Compared to the same quarter last year (YoY), quarterly revenue grew by 9.50%, and quarterly earnings saw a YoY growth of 14.60%.
- How much of APLLTD stock is held by insiders and institutions?
- Wondering who owns Alembic stock? Company insiders (like executives and directors) hold about 70.45% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 16.51%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.